In recent trading session, Harvard Bioscience Inc (NASDAQ:HBIO) saw 3.06 million shares changing hands at last check today with its beta currently measuring 1.54. Company’s recent per share price level of $0.45 trading at $0.04 or 11.16% at last check today assigns it a market valuation of $19.91M. That most recent trading price of HBIO’s stock is at a discount of -700.0% from its 52-week high price of $3.60 and is indicating a premium of 37.78% from its 52-week low price of $0.28. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.72 million shares which gives us an average trading volume of 12.33 million if we extend that period to 3-months.
For Harvard Bioscience Inc (HBIO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Harvard Bioscience Inc (NASDAQ:HBIO) trade information
Upright in the green today for gaining 11.16%, in the last five days HBIO remained trading in the red while hitting it’s week-highest on Thursday, 07/17/25 when the stock touched $0.45 price level, adding 7.02% to its value on the day. Harvard Bioscience Inc’s shares saw a change of -86.44% in year-to-date performance and have moved -2.02% in past 5-day. Harvard Bioscience Inc (NASDAQ:HBIO) showed a performance of -11.59% in past 30-days. Number of shares sold short was 2.83 million shares which calculate 0.09 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 93.57% to its recent value today. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -1455.56% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1455.56% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -18.10% during past 5 years.
Harvard Bioscience Inc (NASDAQ:HBIO)’s Major holders
Insiders are in possession of 8.27% of company’s total shares while institution are holding 69.66 percent of that, with stock having share float percentage of 75.94%. Investors also watch the number of corporate investors in a company very closely, which is 69.66% institutions for Harvard Bioscience Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at HBIO for having 2.84 million shares of worth $8.1 million. And as of 2024-06-30, it was holding 6.5392 of the company’s outstanding shares.
The second largest institutional holder is PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC., which was holding about 2.77 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.3752 of outstanding shares, having a total worth of $7.9 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and HEARTLAND GROUP INC.-HEARTLAND VALUE FUND are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 1.26 shares of worth $0.57 million or 2.85% of the total outstanding shares. The later fund manager was in possession of 1.11 shares on Mar 31, 2025 , making its stake of worth around $0.5 million in the company or a holder of 2.51% of company’s stock.
